ProfileGDS4814 / ILMN_1800700
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 5% 13% 20% 30% 12% 6% 15% 3% 2% 24% 3% 20% 37% 20% 27% 44% 32% 12% 37% 8% 6% 1% 41% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)39.43025
GSM780708Untreated after 4 days (C2_1)41.991713
GSM780709Untreated after 4 days (C3_1)43.597420
GSM780719Untreated after 4 days (C1_2)45.671230
GSM780720Untreated after 4 days (C2_2)41.681612
GSM780721Untreated after 4 days (C3_2)39.65576
GSM780710Trastuzumab treated after 4 days (T1_1)42.482315
GSM780711Trastuzumab treated after 4 days (T2_1)38.29733
GSM780712Trastuzumab treated after 4 days (T3_1)37.06772
GSM780722Trastuzumab treated after 4 days (T1_2)44.438724
GSM780723Trastuzumab treated after 4 days (T2_2)38.04413
GSM780724Trastuzumab treated after 4 days (T3_2)43.570220
GSM780713Pertuzumab treated after 4 days (P1_1)47.05737
GSM780714Pertuzumab treated after 4 days (P2_1)43.460120
GSM780715Pertuzumab treated after 4 days (P3_1)44.979327
GSM780725Pertuzumab treated after 4 days (P1_2)48.713844
GSM780726Pertuzumab treated after 4 days (P2_2)45.925632
GSM780727Pertuzumab treated after 4 days (P3_2)41.805112
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)47.07837
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)40.57438
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)39.86666
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)35.76791
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)47.953141